Search results
Results From The WOW.Com Content Network
The recommendation applies only for areas with high malaria transmission and low resistance against SP, both measures are not free of controversy and only available for few spots in Africa. With the recent drop of malaria transmission in wide stretches of Africa [ 30 ] [ 31 ] and a steady increase in SP resistance [ 32 ] [ 33 ] few malaria ...
The Malaria Journal is a peer-reviewed open access medical journal published by BioMed Central. It was established in 2002 [ 1 ] and covers research on malaria and related topics. The editor-in-chief is Marcel Hommel ( University of Liverpool ).
The major commercial manufacturer of mefloquine-based malaria treatment is Roche Pharmaceuticals, which markets the drug under the trade name Lariam. Lariam is fairly expensive at around three € per tablet (pricing of the year 2000). A dose of 15–25 mg/kg is recommended, depending on the prevalence of mefloquine resistance.
In September 2015, research by MAP published in Nature quantified the attributable effect of malaria disease control efforts in Africa. The results showed Plasmodium falciparum infection prevalence in endemic Africa halved and the incidence of clinical disease fell by 40% between 2000 and 2015. The best estimate is that interventions have ...
Africa Media Review; Africa Renewal; Africa Research Bulletin; Africa Review of Books; Africa, Rivista semestrale di studi e ricerche, successor of Africa: Rivista trimestrale di studi e documentazione; Africa Spectrum; Africa Today; Africa Update; Africa Week; Africa Yearbook; Africa-Asia Confidential; African Affairs; African and Asian ...
Research remains an important aspect of Malaria Consortium's strategy and the organization publishes research in open access and scholarly journals. For instance, it worked with Cambodian National Center for Parasitology, Entomology and Malaria Control and WHO, contributing on research regarding the use of Guppy Fishes as part of an integrated ...
The malaria therapy (or malaria inoculation, [1] and sometimes malariotherapy [2]) is an archaic medical procedure of treating diseases using artificial injection of malaria parasites. [3] It is a type of pyrotherapy (or pyretotherapy) by which high fever is induced to stop or eliminate symptoms of certain diseases.
Target Malaria started as a university-based research programme in 2005. Since 2012, the project has expanded to include scientists, social scientists, stakeholder engagement experts, regulatory affairs experts, project management teams, risk assessment specialists and communications professionals from Africa, Europe, and North America.